Home » Stocks » VKTX

Viking Therapeutics, Inc. (VKTX)

Stock Price: $5.90 USD 0.13 (2.25%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 464.70M
Revenue (ttm) n/a
Net Income (ttm) -43.82M
Shares Out 74.78M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.90
Previous Close $5.77
Change ($) 0.13
Change (%) 2.25%
Day's Open 5.84
Day's Range 5.82 - 6.00
Day's Volume 563,438
52-Week Range 5.26 - 10.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, April 28, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...

1 week ago - PRNewsWire

SAN DIEGO, April 21, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...

2 weeks ago - PRNewsWire

SAN DIEGO, April 7, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and e...

1 month ago - PRNewsWire

SAN DIEGO, March 4, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and e...

2 months ago - PRNewsWire

SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...

4 months ago - PRNewsWire

SAN DIEGO, Jan. 5, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...

4 months ago - PRNewsWire

The entire NASH space was shaken by Genfit's trial fiasco; Viking has its own problems. The drug may actually be a wonderful new therapy for NASH/NAFLD patients; however, whether VKTX will benefit from ...

5 months ago - Seeking Alpha

Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.

Other stocks mentioned: APRE, VXRT
5 months ago - The Motley Fool

SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and e...

5 months ago - PRNewsWire

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.

7 months ago - PRNewsWire

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.

8 months ago - PRNewsWire

Bargain stocks don't come much cheaper than this.

Other stocks mentioned: OPK
8 months ago - The Motley Fool

SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.

8 months ago - PRNewsWire

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.

8 months ago - PRNewsWire

Viking Therapeutics: Another Year In Review

8 months ago - Seeking Alpha

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

Other stocks mentioned: DVAX, IBB, IMGN, LXRX, XNCR
8 months ago - 24/7 Wall Street

Viking Therapeutics, Inc.'s (VKTX) CEO Brian Lian on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

SAN DIEGO, July 29, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and end...

9 months ago - PRNewsWire

SAN DIEGO, July 22, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and e...

9 months ago - PRNewsWire

The risk of investing in Viking Therapeutics Inc. (NASDAQ:VKTX) may not be worth the potential rewards, according to a December article in Equities News.

10 months ago - GuruFocus

Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Friday. BMO Capital initiated coverage on the stock with an Outperform rating and a price target of $14 per share.

11 months ago - Benzinga

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: ATRA, DVAX, FIXX, GTHX, IMGN, KDMN
11 months ago - Kiplinger

Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Tuesday, after Chardan initiated coverage on the company's stock with a Buy rating and $15 price target.

1 year ago - Benzinga

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

The small-cap pharma stock didn't stand a chance in the broader market volatility.

1 year ago - The Motley Fool

Healthcare bargain hunters can find good values in quality low-priced stocks.

Other stocks mentioned: AMGN, AMRX, MRTX, VSTM
1 year ago - The Motley Fool

These clinical-stage drugmakers could be a steal at current levels.

Other stocks mentioned: ADAP, AGEN, GILD
1 year ago - The Motley Fool

Flipping The Script On Viking Therapeutics

1 year ago - Seeking Alpha

Viking Therapeutics: Time To Start Scaling In

1 year ago - Seeking Alpha

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Targeting a large and growing disease state, this drug developer's stock requires patience to reap future rewards.

1 year ago - The Motley Fool

One reason that investors continue to do business with full-service brokerage firms is they generate researched and studied investment ideas.

Other stocks mentioned: BTAI, RARE
1 year ago - 24/7 Wall Street

HOOKIPA Pharma and Viking Therapeutics could catch first at some point this year. Here's why.

Other stocks mentioned: HOOK
1 year ago - The Motley Fool

The S&P 500 closed out 2019 with another strong month in December. However, analysts remain optimistic on some top stocks heading into 2020.

Other stocks mentioned: AMZN, CPRX, GLUU, VSLR
1 year ago - Benzinga

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AKCA, AMAG, AXSM, CRON, EIDX, HRTX, LGND ...
1 year ago - Benzinga

I'm Picking Viking Therapeutics For NASH

1 year ago - Seeking Alpha

Can the stock march even higher after its recent rally?

1 year ago - The Motley Fool

The biotech's Q3 update fired up investors.

1 year ago - The Motley Fool

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CPE, GLMD, SIEN, TELL
1 year ago - 24/7 Wall Street

The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).

Other stocks mentioned: ICPT
1 year ago - The Motley Fool

VKTX produced strong data in reducing liver fat in NAFLD patients.

1 year ago - Seeking Alpha

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower profitabilit...

Other stocks mentioned: AKCA, AMAG, EIDX, LGND, MNKD, MRNA, PRTK
1 year ago - 24/7 Wall Street

What you need to know about this high-risk, high-reward biotech stock.

1 year ago - The Motley Fool

It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?

1 year ago - The Motley Fool

Viking Therapeutics' (VKTX) CEO Brian Lian on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

The catalysts these companies enjoy could translate into big returns for shareholders in the coming decades.

Other stocks mentioned: PM, WELL
1 year ago - The Motley Fool

They're risky. You'll have to wait years before any significant revenue comes in.

Other stocks mentioned: CARA, EDIT
1 year ago - The Motley Fool

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phas... [Read more...]

Industry
Biotechnology
IPO Date
Apr 29, 2015
CEO
Brian Lian
Employees
18
Stock Exchange
NASDAQ
Ticker Symbol
VKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is 19.71, which is an increase of 234.07% from the latest price.

Price Target
$19.71
(234.07% upside)
Analyst Consensus: Strong Buy